JCXH-213
/ Immorna
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 03, 2025
JCXH-213-001: One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
(clinicaltrials.gov)
- P=N/A | N=8 | Recruiting | Sponsor: Beijing GoBroad Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Feb 2026 ➔ Aug 2026
Enrollment open • Trial initiation date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1